[go: up one dir, main page]

PE20040577A1 - Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion y medicamentos que las comprenden - Google Patents

Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion y medicamentos que las comprenden

Info

Publication number
PE20040577A1
PE20040577A1 PE2003000613A PE2003000613A PE20040577A1 PE 20040577 A1 PE20040577 A1 PE 20040577A1 PE 2003000613 A PE2003000613 A PE 2003000613A PE 2003000613 A PE2003000613 A PE 2003000613A PE 20040577 A1 PE20040577 A1 PE 20040577A1
Authority
PE
Peru
Prior art keywords
drugs
procedure
preparation
compounds
ring substituted
Prior art date
Application number
PE2003000613A
Other languages
English (en)
Inventor
Hubert Heuer
Stefanie Flohr
Heiner Glombik
Wendelin Frick
Hans-Ludwig Schafer
Werner Kramer
Gerhard Jaehne
Andreas Lindenschmidt
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PE20040577A1 publication Critical patent/PE20040577A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA REFERIDA A COMPUESTOS DE FORMULA I DONDE R1, R2, R3, R4, R5 Y R6 SON CADA UNO H, F, Br, CF3, ALQUILENO (C1-C30)-(LAG)n EN QUE UNO O MAS ATOMOS DE CARBONO DEL RADICAL ALQUILENO PUEDEN ESTAR SUSTITUIDOS POR ARILO, HATEROARILO, HETEROCICLOALQUILO, ENTRE OTROS; n ES 1-5; (LAG)n ES UN RESIDUO DE AZUCAR, DISACARIDO, TRISACARIDO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2,3,4,5,6-PENTAHIDROXIHEXILAMIDA DEL ACIDO 4-(4-{4-[3-[3-(4-FLUOROFENIL)-3-HIDROXIPROPIL]-2-(4-METOXIFENIL)-4-OXOAZETIDIN-1-IL]BENCILCARBAMOIL}FENOXI)BENZOICO; 2,3,4,5,6-PENTAHIDROXIHEXILAMIDA DEL ACIDO 4-(4-{4-[3-(3-HIDROXI-3-FENILPROPIL)-2-OXO-4-FENILAZETIDIN-1-IL]BENCILCARBAMOIL}FENOXI)BENZOICO, ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE HIPERLIPIDEMIAS, ARTERIOESCLEROSIS E HIPOCOLESTEREMIA
PE2003000613A 2002-06-19 2003-06-18 Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion y medicamentos que las comprenden PE20040577A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10227506A DE10227506A1 (de) 2002-06-19 2002-06-19 Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung

Publications (1)

Publication Number Publication Date
PE20040577A1 true PE20040577A1 (es) 2004-10-11

Family

ID=29719281

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000613A PE20040577A1 (es) 2002-06-19 2003-06-18 Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion y medicamentos que las comprenden

Country Status (30)

Country Link
EP (1) EP1517892B1 (es)
JP (1) JP2005533072A (es)
CN (1) CN1662493A (es)
AR (1) AR039689A1 (es)
AT (1) ATE478842T1 (es)
AU (1) AU2003242616B2 (es)
BR (1) BR0311940A (es)
CA (1) CA2490109A1 (es)
DE (2) DE10227506A1 (es)
EC (1) ECSP045498A (es)
HN (1) HN2003000183A (es)
HR (1) HRP20041203A2 (es)
IL (1) IL165791A0 (es)
MA (1) MA27252A1 (es)
MX (1) MXPA04012236A (es)
MY (1) MY135850A (es)
NO (1) NO20050073L (es)
NZ (1) NZ537304A (es)
OA (1) OA12868A (es)
PA (1) PA8576001A1 (es)
PE (1) PE20040577A1 (es)
PL (1) PL372690A1 (es)
RS (1) RS108504A (es)
RU (1) RU2315754C2 (es)
SV (1) SV2004001549A (es)
TN (1) TNSN04255A1 (es)
TW (1) TW200404774A (es)
UY (1) UY27851A1 (es)
WO (1) WO2004000804A1 (es)
ZA (1) ZA200409381B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7447226B2 (en) * 2003-10-31 2008-11-04 International Business Machines Corporation Methods and apparatus for continuous connectivity between mobile device and network using dynamic connection spreading
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US7700597B2 (en) 2004-12-03 2010-04-20 Schering Corporation Substituted piperazines as CB1 antagonists
EP1865947A1 (en) * 2005-04-04 2007-12-19 Pontificia Universidad Catolica de Chile The use of ezetimibe in the prevention and treatment of cholesterol gallstones
ATE450526T1 (de) 2005-06-20 2009-12-15 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
KR20090047458A (ko) 2006-08-08 2009-05-12 사노피-아벤티스 아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도
AU2007315327A1 (en) * 2006-11-02 2008-05-08 Sanofi-Aventis Deutschland Gmbh Novel diphenylazetidinone substituted by piperazine-1-sulfonic acid having improved pharmacological properties
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
KR100311554B1 (ko) * 1995-10-31 2002-06-20 둘락 노먼 씨. 콜레스테롤저하제로유용한슈가-치환된2-아제티디논
DE10042447A1 (de) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports

Also Published As

Publication number Publication date
HRP20041203A2 (en) 2005-06-30
CA2490109A1 (en) 2003-12-31
ZA200409381B (en) 2006-05-31
TW200404774A (en) 2004-04-01
ECSP045498A (es) 2005-03-10
RU2315754C2 (ru) 2008-01-27
AR039689A1 (es) 2005-03-09
PL372690A1 (en) 2005-07-25
TNSN04255A1 (en) 2007-03-12
DE50313017D1 (de) 2010-10-07
JP2005533072A (ja) 2005-11-04
AU2003242616B2 (en) 2008-12-11
MY135850A (en) 2008-07-31
PA8576001A1 (es) 2004-02-07
WO2004000804A1 (de) 2003-12-31
NZ537304A (en) 2005-10-28
HN2003000183A (es) 2003-08-01
EP1517892B1 (de) 2010-08-25
UY27851A1 (es) 2003-12-31
ATE478842T1 (de) 2010-09-15
AU2003242616A1 (en) 2004-01-06
RS108504A (sr) 2007-02-05
SV2004001549A (es) 2004-03-19
DE10227506A1 (de) 2004-01-08
BR0311940A (pt) 2005-04-05
EP1517892A1 (de) 2005-03-30
RU2005101091A (ru) 2005-07-10
NO20050073L (no) 2005-01-06
OA12868A (en) 2006-09-15
IL165791A0 (en) 2006-01-15
CN1662493A (zh) 2005-08-31
MA27252A1 (fr) 2005-03-01
MXPA04012236A (es) 2005-02-25

Similar Documents

Publication Publication Date Title
PE20040577A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion y medicamentos que las comprenden
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
PE20040892A1 (es) Antagonistas del receptor muscarinico m3 de acetilcolina
PE20040655A1 (es) Nuevos derivados de glicosido de tiofeno, procedimientos para su preparacion y medicamentos que los contienen
PE20011010A1 (es) Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
PE20040960A1 (es) Derivados de piperazina acilados como agonistas del receptor de melanocortina-4
CY1111660T1 (el) Χρηση παραγωγων θειενοπυριδονης ως ενεργοποιητες αμρκ και φαρμακευτικες συνθεσεις που τις περιεχουν
PE20051146A1 (es) Compuestos heterociclicos anticitocina
NO20051165L (no) Benzotiazolderivater som har -adrenoerseptorantagonist aktivitet
RU2012129737A (ru) Замещенные бензамидные производные
PE20010206A1 (es) Acidos o-aminosulfonil-acetohidroxamicos como inhibidores de metaloproteasas
NZ614305A (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
DE602005027881D1 (de) Indolinverbindung und verfahren zu deren herstellung
EA200301216A1 (ru) Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
BRPI0608436A2 (pt) derivados de n-(n-sulfonilaminometil) ciclopropanocarboxamida utilizáveis para o tratamento de dor
PE20040458A1 (es) Piridinas sustituidas con actividad anti-angiogenica
EA200500304A1 (ru) Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
PE20090218A1 (es) Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas
PE20040864A1 (es) Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
PE20050326A1 (es) Derivados de dioxido de tiazol-benzoisotiazol sustituidos como inhibidores de la actividad de la fosfatasa fosfotirosina 1b (ptp1b)
PE20050079A1 (es) Derivados de pirrolidona como inhibidores de maob
UY29389A1 (es) Derivados sustituidos del ácido1-((4-((((3,3-dimetil-2-oxo-2,3-dihidro-1h-indol-1-il)carbonil)amino)metil)piperidin-1-il)metil)ciclobutanocarboxílico, sales farmaceuticamente aceptables, composiciones que los contienen y aplicaciones.
PE20121280A1 (es) Derivados de (tio)morfolina como moduladores de s1p
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
KR840006633A (ko) 벤족사졸리논 유도체의 제조방법

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FD Application declared void or lapsed